Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia

Silvia Alonso-Lana, Marta Marquié, Agustín Ruiz, Mercè Boada, Silvia Alonso-Lana, Marta Marquié, Agustín Ruiz, Mercè Boada

Abstract

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide and has had unprecedented effects in healthcare systems, economies and society. COVID-19 clinical presentation primarily affects the respiratory system causing bilateral pneumonia, but it is increasingly being recognized as a systemic disease, with neurologic manifestations reported in patients with mild symptoms but, most frequently, in those in a severe condition. Elderly individuals are at high risk of developing severe forms of COVID-19 due to factors associated with aging and a higher prevalence of medical comorbidities and, therefore, they are more vulnerable to possible lasting neuropsychiatric and cognitive impairments. Several reports have described insomnia, depressed mood, anxiety, post-traumatic stress disorder and cognitive impairment in a proportion of patients after discharge from the hospital. The potential mechanisms underlying these symptoms are not fully understood but are probably multifactorial, involving direct neurotrophic effect of SARS-CoV-2, consequences of long intensive care unit stays, the use of mechanical ventilation and sedative drugs, brain hypoxia, systemic inflammation, secondary effects of medications used to treat COVID-19 and dysfunction of peripheral organs. Chronic diseases such as dementia are a particular concern not only because they are associated with higher rates of hospitalization and mortality but also because COVID-19 further exacerbates the vulnerability of those with cognitive impairment. In patients with dementia, COVID-19 frequently has an atypical presentation with mental status changes complicating the early identification of cases. COVID-19 has had a dramatical impact in long-term care facilities, where rates of infection and mortality have been very high. Community measures implemented to slow the spread of the virus have forced to social distancing and cancelation of cognitive stimulation programs, which may have contributed to generate loneliness, behavioral symptoms and worsening of cognition in patients with dementia. COVID-19 has impacted the functioning of Memory Clinics, research programs and clinical trials in the Alzheimer's field, triggering the implementation of telemedicine. COVID-19 survivors should be periodically evaluated with comprehensive cognitive and neuropsychiatric assessments, and specific mental health and cognitive rehabilitation programs should be provided for those suffering long-term cognitive and psychiatric sequelae.

Keywords: Alzheimer; COVID-19; SARS-CoV-2; cognition; dementia; neuropsychiatry; pandemics.

Copyright © 2020 Alonso-Lana, Marquié, Ruiz and Boada.

Figures

FIGURE 1
FIGURE 1
Possible mechanisms involved in the neurological manifestations of COVID-19.

References

    1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., et al. (2000). Inflammation and Alzheimer’s disease. Neurobiol. Aging 21 383–421.
    1. Alzheimer’s Association (2020). Coronavirus (COVID-19): Tips for Dementia Caregivers. Available online at: )-tips-for-dementia-care (accessed July 24, 2020).
    1. Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F. X., Chong M., et al. (2020). Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA 323 1612–1614. 10.1001/jama.2020.4326
    1. Balli N., Kara E., Demirkan K. (2020). The another side of COVID-19 in Alzheimer’s disease patients: drug-drug interactions. Int. J. Clin. Pract. 74:e13596.
    1. Batty G. D., Deary I. J., Luciano M., Altschul D. M., Kivimaki M., Gale C. R. (2020). Psychosocial factors and hospitalisations for COVID-19: prospective cohort study based on a community sample. Brain Behav. Immun. 10.1016/j.bbi.2020.06.021 [Epub ahead of print].
    1. Benaque A., Gurruchaga M. J., Abdelnour C., Hernandez I., Canabate P., Alegret M., et al. (2020). Dementia care in times of COVID-19: experience at Fundacio ACE in Barcelona. Spain. J. Alzheimers Dis. 76 33–40. 10.3233/jad-200547
    1. Bianchetti A., Rozzini R., Guerini F., Boffelli S., Ranieri P., Minelli G., et al. (2020). Clinical presentation of COVID19 in Dementia patients. J. Nutr. Health Aging 24 560–562. 10.1007/s12603-020-1389-1
    1. Bilder R. M., Postal K. S., Barisa M., Aase D. M., Cullum C. M., Gillaspy S. R. (2020). InterOrganizational practice committee recommendations/guidance for teleneuropsychology (TeleNP) in response to the COVID-19 pandemic. Clin. Neuropsychol. 10.1080/13854046.2020.1767214 [Epub ahead of print].
    1. Blackman C., Farber S., Feifer R. A., Mor V., White E. M. (2020). An illustration of SARS-CoV-2 dissemination within a skilled nursing facility using heat maps. J. Am. Geriatr. Soc. 10.1111/jgs.16642 [Epub ahead of print].
    1. Borges Do Nascimento I. J., Cacic N., Abdulazeem H. M., Von Groote T. C., Jayarajah U., et al. (2020). Novel Coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J. Clin. Med. 9:941.
    1. Bostanciklioglu M. (2020). Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research. Curr. Neurovasc. Res. 10.2174/1567202617666200522220509 [Epub ahead of print].
    1. Boutoleau-Bretonniere C., Pouclet-Courtemanche H., Gillet A., Bernard A., Deruet A. L., Gouraud I., et al. (2020). The effects of confinement on neuropsychiatric symptoms in Alzheimer’s disease during the COVID-19 crisis. J. Alzheimers Dis. 76 41–47. 10.3233/jad-200604
    1. Brown E. E., Kumar S., Rajji T. K., Pollock B. G., Mulsant B. H. (2020). Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. Am. J. Geriatr. Psychiatry 28 712–721. 10.1016/j.jagp.2020.04.010
    1. Cai X., Hu X., Otte E. I., Wang J., An Y., Li Z., et al. (2020). Psychological distress and its correlates among COVID-19 survivors during early convalescence across age groups. Am. J. Geriatr. Psychiatry 28 1030–1039. 10.1016/j.jagp.2020.07.003
    1. Canevelli M., Valletta M., Toccaceli Blasi M., Remoli G., Sarti G., Nuti F., et al. (2020). Facing dementia during the COVID-19 outbreak. J. Am. Geriatr. Soc. 68 1673–1676. 10.1111/jgs.16644
    1. Capozzo R., Zoccolella S., Frisullo M. E., Barone R., Dell’abate M. T., Barulli M. R., et al. (2020). Telemedicine for delivery of care in frontotemporal lobar degeneration during COVID-19 pandemic: results from Southern Italy. J. Alzheimers Dis. 76 481–489.
    1. Centers for Disease Control and Prevention (2020). COVIDView: A Weekly Surveillance Summary of US COVID-19 activity. Key updates for week, 29. Available online at: (accessed July 28, 2020).
    1. Chaumont H., San-Galli A., Martino F., Couratier C., Joguet G., Carles M., et al. (2020). Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. J. Neurol. 10.1007/s00415-020-09986-y [Epub ahead of print].
    1. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130 2620–2629. 10.1172/jci137244
    1. Cipriani G., Danti S., Nuti A., Carlesi C., Lucetti C., Di Fiorino M. (2020). A complication of coronavirus disease 2019: delirium. Acta Neurol Belg. 120 927–932. 10.1007/s13760-020-01401-7
    1. Cipriani G., Fiorino M. D. (2020). Access to care for dementia patients suffering from COVID-19. Am. J. Geriatr. Psychiatry 28 796–797. 10.1016/j.jagp.2020.04.009
    1. Coolen T., Lolli V., Sadeghi N., Rovai A., Trotta N., Taccone F. S. (2020). Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology 95 e2016–e2027. 10.1212/WNL.0000000000010116
    1. Cordasco F., Scalise C., Sacco M. A., Bonetta C. F., Zibetti A., Cacciatore G., et al. (2020). The silent deaths of the elderly in long-term care facilities during the Covid-19 pandemic: the role of forensic pathology. Med. Leg. J. 88 66–68. 10.1177/0025817220930552
    1. Courtin E., Knapp M. (2017). Social isolation, loneliness and health in old age: a scoping review. Health Soc. Care Community 25 799–812. 10.1111/hsc.12311
    1. Dantzer R. (2018). Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol. Rev. 98 477–504. 10.1152/physrev.00039.2016
    1. Desai S. V., Law T. J., Needham D. M. (2011). Long-term complications of critical care. Crit. Care Med. 39 371–379. 10.1097/ccm.0b013e3181fd66e5
    1. Dinakaran D., Manjunatha N., Naveen Kumar C., Suresh B. M. (2020). Neuropsychiatric aspects of COVID-19 pandemic: a selective review. Asian J. Psychiatr. 53:102188. 10.1016/j.ajp.2020.102188
    1. Ellul M. A., Benjamin L., Singh B., Lant S., Michael B. D., Easton A., et al. (2020). Neurological associations of COVID-19. Lancet Neurol. 19 767–783. 10.1016/S1474-4422(20)30221-0
    1. Frank-Cannon T. C., Alto L. T., Mcalpine F. E., Tansey M. G. (2009). Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 4:47. 10.1186/1750-1326-4-47
    1. Geerts H., van der Graaf P. H. (2020). Salvaging CNS Clinical Trials Halted Due to COVID-19. CPT Pharmacometrics Syst. Pharmacol. 9 367–370. 10.1002/psp4.12535
    1. Goodman-Casanova J. M., Dura-Perez E., Guzman-Parra J., Cuesta-Vargas A., Mayoral-Cleries F. (2020). Telehealth home support during COVID-19 confinement for community-dwelling older adults with mild cognitive impairment or mild dementia: survey study. J. Med. Internet Res. 22:e19434. 10.2196/19434
    1. Goujon A., Natale F., Ghio D., Conte A., Dijkstra L. (2020). Age, Gender, and Territory of COVID-19 Infections and Fatalities, EUR 30237 EN. Luxembourg: Publications Office of the European Union.
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A. (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323 1574–1581. 10.1001/jama.2020.5394
    1. Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., et al. (2020). Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 382 2268–2270. 10.1056/nejmc2008597
    1. Heneka M. T., Golenbock D., Latz E., Morgan D., Brown R. (2020). Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res. Ther. 12:69.
    1. Herridge M. S., Moss M., Hough C. L., Hopkins R. O., Rice T. W., Bienvenu O. J., et al. (2016). Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 42 725–738. 10.1007/s00134-016-4321-8
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181 271–280.e8.
    1. Holt-Lunstad J., Smith T. B., Baker M., Harris T., Stephenson D. (2015). Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect. Psychol. Sci. 10 227–237. 10.1177/1745691614568352
    1. Holwerda T. J., Deeg D. J., Beekman A. T., Van Tilburg T. G., Stek M. L., Jonker C., et al. (2014). Feelings of loneliness, but not social isolation, predict dementia onset: results from the Amsterdam Study of the Elderly (AMSTEL). J. Neurol. Neurosurg. Psychiatry 85 135–142. 10.1136/jnnp-2012-302755
    1. Hopkins R. O., Gale S. D., Weaver L. K. (2006). Brain atrophy and cognitive impairment in survivors of Acute Respiratory Distress Syndrome. Brain Inj. 20 263–271. 10.1080/02699050500488199
    1. Hopkins R. O., Weaver L. K., Collingridge D., Parkinson R. B., Chan K. J., Orme J. F., Jr. (2005). Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 171 340–347. 10.1164/rccm.200406-763oc
    1. Hopkins R. O., Weaver L. K., Pope D., Orme J. F., Bigler E. D., Larson L. V. (1999). Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 160 50–56. 10.1164/ajrccm.160.1.9708059
    1. Hosseini S., Wilk E., Michaelsen-Preusse K., Gerhauser I., Baumgartner W., Geffers R., et al. (2018). Long-term neuroinflammation induced by Influenza A virus infection and the impact on hippocampal neuron morphology and function. J. Neurosci. 38 3060–3080. 10.1523/jneurosci.1740-17.2018
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 497–506.
    1. Hwang J. M., Kim J. H., Park J. S., Chang M. C., Park D. (2020). Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol. Sci. 41 2317–2324. 10.1007/s10072-020-04541-z
    1. Isaia G., Marinello R., Tibaldi V., Tamone C., Bo M. (2020). Atypical presentation of Covid-19 in an older adult with severe Alzheimer disease. Am. J. Geriatr. Psychiatry 28 790–791. 10.1016/j.jagp.2020.04.018
    1. Itzhaki R. F., Lin W. R., Shang D., Wilcock G. K., Faragher B., Jamieson G. A. (1997). Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet 349 241–244. 10.1016/s0140-6736(96)10149-5
    1. Jacomy H., Fragoso G., Almazan G., Mushynski W. E., Talbot P. J. (2006). Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. Virology 349 335–346. 10.1016/j.virol.2006.01.049
    1. Kehoe P. G., Wong S., Al Mulhim N., Palmer L. E., Miners J. S. (2016). Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology. Alzheimers Res. Ther. 8:50.
    1. Kim H. C., Yoo S. Y., Lee B. H., Lee S. H., Shin H. S. (2018). Psychiatric findings in suspected and confirmed middle east respiratory syndrome patients quarantined in hospital: a retrospective chart analysis. Psychiatry Investig. 15 355–360. 10.30773/pi.2017.10.25.1
    1. Koenigsknecht-Talboo J., Landreth G. E. (2005). Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25 8240–8249. 10.1523/jneurosci.1808-05.2005
    1. Kuo C. L., Pilling L. C., Atkins J. L., Masoli J. A. H., Delgado J., Kuchel G. A., et al. (2020). ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank. J. Gerontol. A Biol. Sci. Med. Sci. 75 1801–1803. 10.1093/gerona/glaa169
    1. Lam M. H., Wing Y. K., Yu M. W., Leung C. M., Ma R. C., Kong A. P., et al. (2009). Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch. Intern. Med. 169 2142–2147. 10.1001/archinternmed.2009.384
    1. Lara B., Carnes A., Dakterzada F., Benitez I., Pinol-Ripoll G. (2020). Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID-19 lockdown. Eur. J. Neurol. 10.1111/ene.14339 [Epub ahead of print].
    1. Lechien J. R., Chiesa-Estomba C. M., Place S., Van Laethem Y., Cabaraux P., Mat Q. (2020). Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J. Intern. Med. 288 335–344. 10.1111/joim.13089
    1. Liguori C., Pierantozzi M., Spanetta M., Sarmati L., Cesta N., Iannetta M. (2020). Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav. Immun. 88 11–16. 10.1016/j.bbi.2020.05.037
    1. Lithander F. E., Neumann S., Tenison E., Lloyd K., Welsh T. J., Rodrigues J. C. L., et al. (2020). COVID-19 in older people: a rapid clinical review. Age Ageing 49 501–515.
    1. Lu L., Zhong W., Bian Z., Li Z., Zhang K., Liang B., et al. (2020). A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: a systematic review and meta-analysis. J. Infect. 81 e18–e25. 10.1016/j.jinf.2020.07.002
    1. Marra A., Pandharipande P. P., Girard T. D., Patel M. B., Hughes C. G., Jackson J. C., et al. (2018). Co-occurrence of post-intensive care syndrome problems among 406 survivors of critical illness. Crit. Care Med. 46 1393–1401. 10.1097/ccm.0000000000003218
    1. Martin-Sanchez F. J., Del Toro E., Cardassay E., Valls Carbo A., Cuesta F., Vigara M. (2020). Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department. Eur. Geriatr. Med. 10.1007/s41999-020-00359-2 [Epub ahead of print].
    1. McLoughlin B. C., Miles A., Webb T. E., Knopp P., Eyres C., Fabbri A., et al. (2020). Functional and cognitive outcomes after COVID-19 delirium. Eur. Geriatr. Med. 10.1007/s41999-020-00353-8 [Epub ahead of print].
    1. McMichael T. M., Currie D. W., Clark S., Pogosjans S., Kay M., Schwartz N. G. (2020). Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N. Engl. J. Med. 382 2005–2011.
    1. Miyashita S., Yamada T., Mikami T., Miyashita H., Chopra N., Rizk D. (2020). Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York. Geriatr. Gerontol. Int. 20 732–734. 10.1111/ggi.13942
    1. Nalleballe K., Reddy Onteddu S., Sharma R., Dandu V., Brown A., Jasti M., et al. (2020). Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav. Immun. 88 71–74. 10.1016/j.bbi.2020.06.020
    1. Netland J., Meyerholz D. K., Moore S., Cassell M., Perlman S. (2008). Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 82 7264–7275. 10.1128/jvi.00737-08
    1. Ogier M., Andeol G., Sagui E., Bo G. D. (2020). How to detect and track chronic neurologic sequelae of Covid-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. Brain Behav. Immun. Health 5:100081. 10.1016/j.bbih.2020.100081
    1. Ousset P. J., Vellas B. (2020). Viewpoint: impact of the Covid-19 outbreak on the clinical and research activities of memory clinics: an Alzheimer’s disease center facing the Covid-19 crisis. J. Prev. Alzheimers Dis. 7 197–198.
    1. Padala S. P., Jendro A. M., Orr L. C. (2020). Facetime to reduce behavioral problems in a nursing home resident with Alzheimer’s dementia during COVID-19. Psychiatry Res. 288:113028. 10.1016/j.psychres.2020.113028
    1. Parra A., Juanes A., Losada C. P., Alvarez-Sesmero S., Santana V. D., Marti I., et al. (2020). Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Res. 291:113254. 10.1016/j.psychres.2020.113254
    1. Paterson R. W., Brown R. L., Benjamin L., Nortley R., Wiethoff S., Bharucha T. (2020). The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 10.1093/brain/awaa240 [Epub ahead of print].
    1. Perez-Grijalba V., Romero J., Pesini P., Sarasa L., Monleon I., San-Jose I. (2019). Plasma Abeta42/40 ratio detects early stages of Alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J. Prev. Alzheimers Dis. 6 34–41.
    1. Pinna P., Grewal P., Hall J. P., Tavarez T., Dafer R. M., Garg R. (2020). Neurological manifestations and COVID-19: experiences from a tertiary care center at the Frontline. J. Neurol. Sci. 415:116969. 10.1016/j.jns.2020.116969
    1. Pinzon R. T., Wijaya V. O., Buana R. B., Al Jody A., Nunsio P. N. (2020). Neurologic characteristics in Coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front. Neurol. 11:565. 10.3389/fneur.2020.00565
    1. Puelles V. G., Lutgehetmann M., Lindenmeyer M. T., Sperhake J. P., Wong M. N., Allweiss L. (2020). Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383 590–592. 10.1056/NEJMc2011400
    1. Rea I. M., Gibson D. S., Mcgilligan V., Mcnerlan S. E., Alexander H. D., Ross O. A. (2018). Age and age-related diseases: role of inflammation triggers and cytokines. Front. Immunol. 9:586. 10.3389/fimmu.2018.00586
    1. Reichard R. R., Kashani K. B., Boire N. A., Constantopoulos E., Guo Y., Lucchinetti C. F. (2020). Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 140 1–6. 10.1007/s00401-020-02166-2
    1. Richardson S. J., Carroll C. B., Close J., Gordon A. L., O’brien J., Quinn T. J. (2020). Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities. Age Ageing. 10.1093/ageing/afaa149 [Epub ahead of print].
    1. Rita Egbert A., Cankurtaran S., Karpiak S. (2020). Brain abnormalities in COVID-19 acute/subacute phase: a rapid systematic review. Brain Behav. Immun. 10.1016/j.bbi.2020.07.014 [Epub ahead of print].
    1. Rogers J. P., Chesney E., Oliver D., Pollak T. A., Mcguire P., Fusar-Poli P., et al. (2020). Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7 611–627. 10.1016/s2215-0366(20)30203-0
    1. Roman G. C., Spencer P. S., Reis J., Buguet A., Faris M. E. A., Katrak S. M. (2020). The neurology of COVID-19 revisited: a proposal from the environmental neurology specialty group of the world federation of neurology to implement international neurological registries. J. Neurol. Sci. 414:116884. 10.1016/j.jns.2020.116884
    1. Romero-Sanchez C. M., Diaz-Maroto I., Fernandez-Diaz E., Sanchez-Larsen A., Layos-Romero A., Garcia-Garcia J. (2020). Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 95 e1060–e1070. 10.1212/WNL.0000000000009937
    1. Sasannejad C., Ely E. W., Lahiri S. (2019). Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit. Care 23:352.
    1. Solomon I. H., Normandin E., Bhattacharyya S., Mukerji S. S., Keller K., Ali A. S., et al. (2020). Neuropathological features of Covid-19. N. Engl. J. Med. 383 989–992. 10.1056/NEJMc2019373
    1. Suzuki M., Hotta M., Nagase A., Yamamoto Y., Hirakawa N., Satake Y. (2020). The behavioral pattern of patients with frontotemporal dementia during the COVID-19 pandemic. Int. Psychogeriatr. 10.1017/S104161022000109X [Epub ahead of print].
    1. Sy M., Kitazawa M., Medeiros R., Whitman L., Cheng D., Lane T. E., et al. (2011). Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am. J. Pathol. 178 2811–2822. 10.1016/j.ajpath.2011.02.012
    1. The Food and Drug Administration (2020). FDA Guidance on Conduct of Clinical Trials of Medical Products DURING COVID-19 Public Health Emergency. Available online at: (accessed July 24, 2020).
    1. Troyer E. A., Kohn J. N., Hong S. (2020). Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 87 34–39. 10.1016/j.bbi.2020.04.027
    1. Tsai S. T., Lu M. K., San S., Tsai C. H. (2020). The neurologic manifestations of Coronavirus disease 2019 pandemic: a systemic review. Front. Neurol. 11:498. 10.3389/fneur.2020.00498
    1. University of Liverpool (2020). COVID-19 Drug Interactions. Available online at: (accessed July 24, 2020).
    1. Varatharaj A., Thomas N., Ellul M. A., Davies N. W. S., Pollak T. A., Tenorio E. L. (2020). Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7 875–882. 10.1016/S2215-0366(20)30287-X
    1. Vindegaard N., Benros M. E. (2020). COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav. Immun. 10.1016/j.bbi.2020.05.048 [Epub ahead of print].
    1. Walker K. A., Gottesman R. F., Wu A., Knopman D. S., Gross A. L., Mosley T. H., et al. (2019). Systemic inflammation during midlife and cognitive change over 20 years: the ARIC Study. Neurology 92 e1256–e1267.
    1. Ward C. F., Figiel G. S., Mcdonald W. M. (2020). Altered mental status as a novel initial clinical presentation for COVID-19 infection in the elderly. Am. J. Geriatr. Psychiatry 28 808–811. 10.1016/j.jagp.2020.05.013
    1. Weinberg M. S., Patrick R. E., Schwab N. A., Owoyemi P., May R., Mcmanus A. J., et al. (2020). Clinical trials and tribulations in the COVID-19 era. Am. J. Geriatr. Psychiatry 28 913–920. 10.1016/j.jagp.2020.05.016
    1. Williamson E. J., Walker A. J., Bhaskaran K., Bacon S., Bates C., Morton C. E. (2020). OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature 584 430–436.
    1. World Health Organization (2020). Coronavirus Disease (COVID-19) Situation Report-190. Available online at: (accessed September 28, 2020).
    1. Wu Z., McGoogan J. M. (2020). Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 323 1239–1242. 10.1001/jama.2020.2648
    1. Xia H., Lazartigues E. (2008). Angiotensin-converting enzyme 2 in the brain: properties and future directions. J. Neurochem. 107 1482–1494. 10.1111/j.1471-4159.2008.05723.x
    1. Yang Y., Shen C., Li J., Yuan J., Wei J., Huang F. (2020). Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J. Allergy Clin. Immunol. 146 119–127.e4.
    1. Yuan B., Li W., Liu H., Cai X., Song S., Zhao J. (2020). Correlation between immune response and self-reported depression during convalescence from COVID-19. Brain Behav. Immun. 88 39–43. 10.1016/j.bbi.2020.05.062
    1. Zhang J., Lu H., Zeng H., Zhang S., Du Q., Jiang T., et al. (2020). The differential psychological distress of populations affected by the COVID-19 pandemic. Brain Behav. Immun. 87 49–50. 10.1016/j.bbi.2020.04.031
    1. Zubair A. S., Mcalpine L. S., Gardin T., Farhadian S., Kuruvilla D. E., Spudich S. (2020). Neuropathogenesis and neurologic manifestations of the Coronaviruses in the age of Coronavirus disease 2019: a review. JAMA Neurol. 77 1018–1027. 10.1001/jamaneurol.2020.2065

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever